Literature DB >> 11299762

IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid.

B A Narayanan1, G G Re.   

Abstract

Altered cell and tissue differentiation is characteristic of premalignant lesions long before they become invasive and metastatic. One approach to controlling preneoplastic lesions is to block their expansion with non-toxic agents that suppress cell proliferation and induce apoptosis. Here, we show that ellagic acid, a natural, dietary phenolic antioxidant when given at 10(-5) M for 48 hours to colon cancer cells (SW 480), induced down regulation of insulin like growth factor IGF-II, activated p21(waf1/Cip1), mediated a cumulative effect on G1/S transition phase and caused apoptotic cell death. SW480 colon cancer cells expressed significant mRNA levels for the mitogenic insulin like growth factor (IGF-II). Collectively, these observations suggest that growth inhibition by ellagic acid is mediated by signaling pathways that mediate DNA damage, triggers p53, which in turn activates p21 and at the same time alters the growth factor expression, resulting in the down regulation of IGF-II.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299762

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Insulin-like growth factor-II gene polymorphism is associated with primary open angle glaucoma.

Authors:  Fuu-Jen Tsai; Hui-Ju Lin; Wen-Chi Chen; Huey-Yi Chen; Seng-Sheen Fan
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

2.  Ellagic acid and human cancers: a systems pharmacology and docking study to identify principal hub genes and main mechanisms of action.

Authors:  Hamid Cheshomi; Ahmad Reza Bahrami; Maryam M Matin
Journal:  Mol Divers       Date:  2020-05-14       Impact factor: 2.943

3.  Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation.

Authors:  Sheng-Teng Huang; Rong-Chi Yang; Hsiao-Ting Wu; Chao-Nin Wang; Jong-Hwei S Pang
Journal:  PLoS One       Date:  2011-05-04       Impact factor: 3.240

4.  Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.

Authors:  Laura H Engelke; Alexandra Hamacher; Peter Proksch; Matthias U Kassack
Journal:  J Cancer       Date:  2016-01-10       Impact factor: 4.207

Review 5.  Honey and Cancer: Current Status and Future Directions.

Authors:  Laura M Porcza; Claire Simms; Mridula Chopra
Journal:  Diseases       Date:  2016-09-30

6.  Polyphenol Extract from Evening Primrose (Oenothera paradoxa) Inhibits Invasion Properties of Human Malignant Pleural Mesothelioma Cells.

Authors:  Malgorzata Chmielewska-Kassassir; Katarzyna Sobierajska; Wojciech M Ciszewski; Malgorzata Bukowiecka-Matusiak; Dorota Szczesna; Izabela Burzynska-Pedziwiatr; Wieslaw Wiczkowski; Waldemar Wagner; Lucyna A Wozniak
Journal:  Biomolecules       Date:  2020-11-19

7.  Ellagic Acid Reduces Adipogenesis through Inhibition of Differentiation-Prevention of the Induction of Rb Phosphorylation in 3T3-L1 Adipocytes.

Authors:  Lifeng Wang; Linlin Li; Xinjian Ran; Mei Long; Minfang Zhang; Yicun Tao; Xin Luo; Ye Wang; Xiaoli Ma; Upur Halmurati; Xinmin Mao; Jun Ren
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-04       Impact factor: 2.629

8.  Apoptotic efficacy of biogenic silver nanoparticles on human breast cancer MCF-7 cell lines.

Authors:  Jannathul Firdhouse M; Lalitha P
Journal:  Prog Biomater       Date:  2015-10-23

Review 9.  Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid.

Authors:  Claudia Ceci; Pedro M Lacal; Lucio Tentori; Maria Gabriella De Martino; Roberto Miano; Grazia Graziani
Journal:  Nutrients       Date:  2018-11-14       Impact factor: 5.717

10.  Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation.

Authors:  Deena S Mousa; Ali H El-Far; Amna A Saddiq; Thangirala Sudha; Shaker A Mousa
Journal:  Int J Nanomedicine       Date:  2020-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.